Craig Eagle News Today

A panel of U.S. Food and Drug Administration advisers on Thursday recommended approval for a new blood test to detect colon and rectal cancer despite concerns over the test's accuracy.

CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.

The test would not replace any screening methods, but it could be another noninvasive option, to boost the number of people who complete screenings.

Today, a simple blood test developed by Guardant Health in Silicon Valley can detect colon cancer.

More than 53,000 Americans are expected to die from colorectal cancer this year.

COSMOS study shows Guardant Reveal™ blood test highly predictive for disease recurrence in patients with early-stage colon cancer without need for tissue specimen ...

Spotlight sessions highlight role of Guardant blood tests in tissue-free detection of minimal residual disease and predictive impact of ctDNA genomic profiling MRD study found ctDNA detection...

Guardant Health, Inc. , a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas....

PALO ALTO, Calif., October 23, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens in patients with stage III or high-risk stage II colon cancer. Results from the trial, which is an ISS study sponsored by IFOM ETS – the AIRC I...

01.09.2023 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study. The COBRA study was designed to evaluate the effectiveness of using ...